| Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American … NI Lindeman, PT Cagle, DL Aisner, ME Arcila, MB Beasley, EH Bernicker, ... Archives of pathology & laboratory medicine 142 (3), 321-346, 2018 | 1642 | 2018 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1391 | 2018 |
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors EA Akbay, S Koyama, J Carretero, A Altabef, JH Tchaicha, ... Cancer discovery 3 (12), 1355-1363, 2013 | 1352 | 2013 |
| PD-L1 as a biomarker of response to immune-checkpoint inhibitors DB Doroshow, S Bhalla, MB Beasley, LM Sholl, KM Kerr, S Gnjatic, ... Nature reviews Clinical oncology 18 (6), 345-362, 2021 | 1092 | 2021 |
| The 2021 WHO classification of lung tumors: impact of advances since 2015 AG Nicholson, MS Tsao, MB Beasley, AC Borczuk, E Brambilla, ... Journal of Thoracic Oncology 17 (3), 362-387, 2022 | 1043 | 2022 |
| Acquired Resistance to KRASG12C Inhibition in Cancer MM Awad, S Liu, II Rybkin, KC Arbour, J Dilly, VW Zhu, ML Johnson, ... New England Journal of Medicine 384 (25), 2382-2393, 2021 | 806 | 2021 |
| MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met … MM Awad, GR Oxnard, DM Jackman, DO Savukoski, D Hall, P Shivdasani, ... Journal of clinical oncology 34 (7), 721-730, 2016 | 735 | 2016 |
| Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib GR Oxnard, Y Hu, KF Mileham, H Husain, DB Costa, P Tracy, N Feeney, ... JAMA oncology 4 (11), 1527-1534, 2018 | 683 | 2018 |
| Association of polymerase e–mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1 BE Howitt, SA Shukla, LM Sholl, LL Ritterhouse, JC Watkins, S Rodig, ... JAMA oncology 1 (9), 1319-1323, 2015 | 668 | 2015 |
| Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ... Journal of thoracic oncology 13 (9), 1248-1268, 2018 | 634 | 2018 |
| Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors D Miao, CA Margolis, NI Vokes, D Liu, A Taylor-Weiner, SM Wankowicz, ... Nature genetics 50 (9), 1271-1281, 2018 | 546 | 2018 |
| PD-1 inhibitor–related pneumonitis in advanced cancer patients: radiographic patterns and clinical course M Nishino, NH Ramaiya, MM Awad, LM Sholl, JA Maattala, M Taibi, ... Clinical Cancer Research 22 (24), 6051-6060, 2016 | 495 | 2016 |
| Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer C Rolfo, P Mack, GV Scagliotti, C Aggarwal, ME Arcila, F Barlesi, T Bivona, ... Journal of Thoracic Oncology 16 (10), 1647-1662, 2021 | 468 | 2021 |
| Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience LM Sholl, DL Aisner, M Varella-Garcia, LD Berry, D Dias-Santagata, ... Journal of thoracic oncology 10 (5), 768-777, 2015 | 464 | 2015 |
| Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer S Cardarella, A Ogino, M Nishino, M Butaney, J Shen, C Lydon, BY Yeap, ... Clinical cancer research 19 (16), 4532-4540, 2013 | 448 | 2013 |
| Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer EP Garcia, A Minkovsky, Y Jia, MD Ducar, P Shivdasani, X Gong, ... Archives of Pathology and Laboratory Medicine 141 (6), 751-758, 2017 | 446 | 2017 |
| Clinicopathologic features and long-term outcomes of NUT midline carcinoma DE Bauer, CM Mitchell, KM Strait, CS Lathan, EB Stelow, SC Lüer, ... Clinical Cancer Research 18 (20), 5773-5779, 2012 | 429 | 2012 |
| The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy R Scherz-Shouval, S Santagata, ML Mendillo, LM Sholl, I Ben-Aharon, ... Cell 158 (3), 564-578, 2014 | 406 | 2014 |
| Institutional implementation of clinical tumor profiling on an unselected cancer population LM Sholl, K Do, P Shivdasani, E Cerami, AM Dubuc, FC Kuo, EP Garcia, ... JCI insight 1 (19), 2016 | 402 | 2016 |
| Anti–PD-1–related pneumonitis during cancer immunotherapy M Nishino, LM Sholl, H Hatabu, NH Ramaiya, FS Hodi New England Journal of Medicine 373 (3), 288-290, 2015 | 401 | 2015 |
